Cell Therapy Manufacturing Market Size, Share & Growth Trend Analysis Report (2026 - 2035)

Market Outlook

The global cell therapy manufacturing market, valued at USD 6.3 billion in 2025, is projected to reach USD 7.2 billion in 2026 and USD 14.0 billion by 2035, representing a CAGR of 7.7% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• Based on type of cell therapy, the CAR-T cell therapies segment holds the highest share, accounting for nearly 65% of the current market.
• With respect to source of cells, the autologous cells segment dominates the current market, capturing more than 50% of the overall share.
• Based on origin of cells, the bone marrow segment accounts for the largest share within the current market.
• In terms of technology, somatic cell technology captures the largest share in the current year.
• Based on scale of operation, the clinical segment captures the largest share of the current market.
• Amongst the types of manufacturers, contract manufacturing organizations capture the majority share of the current market.
• In terms of key geographical regions, North America currently holds the highest market share in the current year.

Key Market Statistics

• Market Size in 2026: $7.2 Billion
• Estimated Market Size in 2035: $14.0 Billion
• CAGR (2026-2035): 7.7%
• North America: Largest market in 2026
• North America: Fastest growing region

Market Introduction

Over the years, various technological advances and discoveries have significantly changed the practice of medicine. One such advancement is the development of cell-based therapies, which have demonstrated significant therapeutic potential and may help reduce toxicity-related concerns associated with conventional pharmacological interventions.

Researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities across the globe. Further, several organizations are launching initiatives that address manufacturing complexities and support the long-term success of these novel therapies.

Cell and gene therapy manufacturing is a complex process conducted in a highly controlled, contamination-free environment and involves various critical steps such as the isolation, modification, and expansion of immune cells, including T-cells and stem cells. Each step requires specialized systems and strict adherence to regulatory guidelines to ensure product safety, efficacy, and consistency.

The industry is increasingly adopting closed and automated manufacturing platforms to reduce manual intervention, improve process consistency and support scalable production. For instance, Cellares is advancing automated cell therapy manufacturing through its Cell Shuttle platform, which enables end-to-end, closed-system production. Such technologies are expected to help developers reduce operational variability, address logistical challenges, and improve manufacturing efficiency.

Key Players in Cell Therapy Manufacturing Market

Market Segmentation

Based on our research, we have segmented the Cell Therapy Manufacturing Market into type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer and key geographical regions.

By Type of Cell Therapy

• CAR-T Cell Therapies
• Stem Cell Therapies
• TCR Therapies
• TIL Therapies
• Dendritic Cell Therapies
• Other Cell Therapies

By Source of Cells

• Autologous Cells
• Allogeneic Cells

By Origin of Cells

• Induced Pluripotent Stem Cells
• Bone Marrow
• Umbilical Cord
• Adipose Tissue
• Neural Stem Cells
• Others

By Technology

• Somatic Cell Technology
• 3D Bioprinting Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology

By Scale of Operation

• Clinical Scale
• Commercial Scale

By Type of Manufacturer

• In-house Manufacturers
• Contract Manufacturing Organizations

By Key Geographical Regions

• North America
  • US
  • Canada
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific and Rest of the World
  • Argentina
  • Australia
  • Brazil
  • China
  • India
  • Israel
  • Japan
  • Singapore
  • South Africa
  • South Korea
  • Taiwan

Cell Therapy Manufacturing Market Key Insights

What are the Key Drivers for Cell Therapy Manufacturing Market Growth?

• Growing Clinical Pipeline of Cell Therapies: The cell therapy domain is rapidly expanding, with a surge in clinical trials and an increase in regulatory approvals. As more therapies move from early research to late-stage clinical trials, patients have more access to therapies. According to American Society of Gene & Cell Therapy (ASGCT) Q1 2026 report, 2,132 gene therapies, including genetically modified cell therapies such as CAR-T cell therapies, and 881 non-genetically modified cell therapies were in development from preclinical through pre-registration stages. The report also identified 871 open clinical trials for non-genetically modified cell therapies, underscoring the sustained demand for specialized clinical and commercial manufacturing capabilities.
• Emerging Economies to Drive Long-Term Growth: Emerging economies will support long-term growth by developing local cell therapy manufacturing facilities. Companies such as Laurus Labs are focusing on affordable cell therapies, while countries such as India and Saudi Arabia are expanding their manufacturing capacities through new advanced facilities.,

What are the Main Challenges for Market Growth?

• Technical and Operational Intricacies: Although propelled by robust demand, the cell therapy manufacturing sector has several hurdles associated with the transition of cell-based therapy products from laboratory to clinical scale. These challenges include limited skilled professionals, along with regulatory compliance, lack of advanced facilities and infrastructure.
• Scale-Up-Related Challenges: Cell therapy manufacturing processes require sterile, higher-grade clean rooms and stringent monitoring of containment levels to maintain product integrity and compliance. Owing to these complex procedures, scaling up cell therapy manufacturing becomes a bit challenging.

Role of Trump Administration Tariffs on Domestic Production

Due to tariffs imposed on pharmaceuticals by the current administration, there has been an increase in agreements and investments aimed at expanding manufacturing operations in the US. In May 2026, the US Commerce Department launched an application process for pharmaceutical manufacturers seeking reduced Section 232 tariff rates if they commit to expanding or relocating manufacturing operations in the US. This move is aimed at supporting continued investment in domestic advanced therapy manufacturing. For instance, in May 2026, FUJIFILM Cellular Dynamics launched a new iPSC development and manufacturing facility in Madison, Wisconsin, which is expected to quadruple its iPSC manufacturing capacity and support future contract manufacturing of cell therapy products.

Recent Developments in Cell Therapy Manufacturing Market

• In June 2026, Merck agreed to acquire Bio-Techne for approximately USD 11.3 billion. The acquisition is expected to strengthen Merck’s life science capabilities across research, bioprocessing, advanced therapeutics, analytical technologies, and integrated workflow solutions for cell and gene therapy developers.
• In June 2026, CARsgen Therapeutics received approval from China’s drug regulator for satri-cel, a CAR-T therapy for stomach cancer. The approval marks an important milestone for solid tumor CAR-T therapies and is expected to increase demand for specialized CAR-T manufacturing capabilities in Asia-Pacific.
• In June 2026, Minaris enhanced its dedicated GMP cell banking suites at its Philadelphia facility. The upgraded suites strengthen the company’s biosafety testing, GMP analytics, and product characterization capabilities, supporting cell and gene therapy developers across development, scale-up, and commercial manufacturing.
• In June 2026, CCRM and OmniaBio entered into an agreement with Avectas to evaluate its automated cell therapy manufacturing platform. The evaluation will assess how Avectas’ platform can support standardized, automated and scalable manufacturing workflows across CCRM’s global network and OmniaBio’s manufacturing operations.
• In June 2026, Made Scientific entered into a strategic partnership with Pluristyx to integrate GMP iPSC lines and derivative cell types into Made Scientific’s end-to-end CDMO offering. The partnership aims to provide cell therapy developers with a coordinated path from clinical-grade starting material through GMP manufacturing, reducing handoff risk and development timelines.

Industry Experts on Cell Therapy Manufacturing Market

Driven by the need to improve patient access, reduce production variability and support commercial-scale supply, cell therapy manufacturing is shifting toward more standardized, reproducible, and cost-efficient production models.

Emphasizing this shift, Pierre-Alain Ruffieux (Group Executive, Bioprocess, Cytiva) stated, “Cell and gene therapies are often life-changing for patients; however, high costs and technological constraints remain barriers to access. Scaling these therapies globally will require manufacturing that is more consistent, reproducible, and cost-effective. Current processes are complex, often patient-specific, and difficult to reproduce consistently at scale. Progress will depend on increasing standardization and automation to reduce variability and improve process control. Platform-based and modular manufacturing approaches are beginning to address these issues by enabling more predictable scale-up and scale-out.”

Discussions with multiple stakeholders in this domain have influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Marketing Manager, Cell Therapy, Mid-sized Company, Australia
• Director, UK
• Marketing Director, Small Company, Belgium
• Management Board Vice-President, Large Company, Poland
• Senior Director of Sales Advanced Therapies; Vice President of Marketing, Small Company, US
• Business Administration Department Manager, Mid-sized Company, Japan
• Chief Business Officer, Small Company, Netherlands
• Director of Finance and Facility Operations, US
• Senior Director, Very Large Company, Japan
• Chief Executive Officer, Mid-sized Company, UK
• Former Chief Technical Officer, Large Company, US
• Former Chief Executive Officer, Small Company, Netherlands
• Former General Manager, Small Company, France
• Chief Executive Officer, Large Company, China
• Executive Vice President Research and Development, Small Company, Israel
• Former Business Development Manager, Mid-sized Company, UK
• Professor and American Red Cross Chair in Transfusion Medicine, US
• Former Co-Founder and Chief Executive Officer, Small Company, Singapore
• Former Manager, Business Development and Operations-cGMP Manufacturing Unit, Mid-sized Company, Canada
• Manager of Business Development, Small Company, US
• Former Department Leader, Cell Therapy Innovation and Development, Mid-sized Company, France
• Former Chief Executive Officer, Mid-sized Company, Australia
• Chief Executive Officer, Small Company, Netherlands

In addition, the market report includes transcripts of the following other third-party discussions:

• Chief Executive Officer and Co-founder, Mid-sized Company, US
• Chief Executive Officer, Mid-sized Company, UK
• Chief Executive Officer, Small Company, US
• Group Executive, Bioprocess, Very Large Company, US
• Executive Director, Global Scientific Portfolio Management, Cell and Gene Therapy, Very Large Company, US
• Vice President of Regulatory Affairs; Director of Clinical Services and Alliances, Large Company, Canada
• Vice President & Head of Quality & Compliance, Mid-sized Company, US
• Senior Product Manager, Cell Therapy, Large Company, US
• Principal Scientist, Process Development Services, Very Large Company, Germany
• Program Manager, GMP Bioprocessing, Large Company, US

Market Share Insights

Which Type of Cell Therapy Accounts for the Largest Share in the Cell Therapy Manufacturing Market?

Based on type of cell therapy, the global cell therapy manufacturing market is segmented into CAR-T cell therapies, stem cell therapies, TCR cell therapies, TIL cell therapies, dendritic cell therapies, and other cell therapies.

Currently, CAR-T cell therapies account for the largest share of the cell therapy manufacturing market, capturing nearly 65% of the overall market. This dominance is primarily due to the strong clinical and commercial adoption of CAR-T therapies, particularly across hematological malignancies. The segment also benefits from a growing number of approved products, expanding treatment access, and continued investment in specialized manufacturing infrastructure. In addition, CAR-T therapies often involve complex, high-value manufacturing workflows, including cell collection, activation, genetic modification, expansion, quality testing, and release, which significantly increases their contribution to the overall manufacturing market.

The other cell therapies segment, including natural killer cell therapies and genetically modified cell therapies, is likely to grow at a higher CAGR of 16.15% during the forecast period. This growth is driven by increasing interest in next-generation cell therapy platforms that can support broader patient access and improved manufacturing scalability. Natural killer cell therapies, in particular, are gaining traction due to their favorable safety profile, lower risk of graft-versus-host disease, and potential to support off-the-shelf treatment approaches. As developers continue to advance these emerging platforms, demand for manufacturing capabilities across other cell therapy segments is expected to increase significantly.

Among Autologous and Allogeneic, Which Segment Holds the Highest Share in the Cell Therapy Manufacturing Market?

With respect to source of cells, the global cell therapy manufacturing market is segmented into autologous cells and allogeneic cells.

Currently, autologous cells account for the larger share of the cell therapy manufacturing market, capturing more than 50% of the overall market. This dominance is due to the strong clinical adoption of patient-specific therapies, particularly across CAR-T cell therapy manufacturing. Since autologous therapies use a patient’s own cells, they reduce the risk of immune rejection and graft-versus-host disease. Recent approvals, such as Waskyra®, an autologous blood stem cell-based gene therapy for Wiskott-Aldrich syndrome, further highlight the continued clinical relevance of patient-specific cell therapy approaches.

Autologous cells are also likely to grow at a higher rate during the forecast period. This growth is supported by the continued expansion of personalized therapies across oncology and other complex disease areas, where patient-specific manufacturing remains critical. Ongoing improvements in automation, closed-system processing, and quality control workflows are also expected to improve the scalability of autologous cell therapy manufacturing.

What is the Market Opportunity for Induced Pluripotent Stem Cells in the Cell Therapy Manufacturing Market?

Based on origin of cells, the global cell therapy manufacturing market is segmented into induced pluripotent stem cells, bone marrow, umbilical cord, adipose tissue, neural stem cells, and others.

Currently, the bone marrow segment accounts for the largest share of the cell therapy manufacturing market. This dominance is due to the long-established use of bone marrow-derived cells in hematopoietic stem cell transplantation and regenerative medicine applications. The segment also benefits from well-defined collection, processing, and storage protocols, along with extensive clinical validation across multiple therapeutic areas.

Induced pluripotent stem cells are likely to witness significant growth during the forecast period. Their ability to propagate indefinitely and differentiate into multiple specialized cell types makes them suitable for scalable and standardized cell therapy manufacturing. As developers focus on allogeneic, off-the-shelf, and next-generation regenerative medicine platforms, demand for iPSC-derived therapies is expected to increase.

Which Technology Dominates the Cell Therapy Manufacturing Market?

In terms of technology, the global cell therapy manufacturing market is segmented into somatic cell technology, 3D bioprinting technology, cell immortalization technology, viral vector technology, genome editing technology, and cell plasticity technology.

Currently, somatic cell technology captures the largest share of the cell therapy manufacturing market. This dominance is due to its widespread use across established manufacturing workflows, including isolation, processing, expansion, and modification of cells for therapeutic applications. Its strong adoption across CAR-T cell therapies, TCR cell therapies, dendritic cell therapies, and stem cell-based approaches reinforce its role as a core technology in current cell therapy manufacturing operations.

3D bioprinting technology is likely to grow at the highest rate during the forecast period. This growth is supported by its increasing use in developing personalized, cell-laden constructs that mimic native tissue structure and function. Its ability to support precision manufacturing, tissue-specific constructs, and next-generation regenerative medicine applications is expected to drive strong adoption in the coming years.

Regional Analysis: Which Region Dominates the Cell Therapy Manufacturing Market?

In terms of key geographical regions, the global cell therapy manufacturing market is segmented into North America, Europe, Asia-Pacific and the Rest of the World.

North America: Dominating the Market by Securing the Highest Share

According to our analysis, North America captures the largest share of the cell therapy manufacturing market. This dominance is supported by the presence of cell therapy developers, advanced GMP manufacturing infrastructure, established clinical research networks, and a supportive regulatory environment in the US. For instance, in January 2026, the FDA announced a more flexible approach to chemistry, manufacturing, and control requirements for cell and gene therapies to expedite product development and support BLA readiness.

North America is also likely to grow at the highest CAGR during the forecast period, driven by continued expansion of specialized cell therapy manufacturing capacity across the region. For instance, in April 2026, Made Scientific announced a 12,000-square-foot expansion of its Princeton GMP facility, while Johnson & Johnson, in February 2026, announced an investment of more than USD 1 billion to establish a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. These developments are expected to strengthen the region’s position in clinical and commercial cell therapy manufacturing.

Scope of Cell Therapy Manufacturing Market Report